SCHEMBL5658691

SCHEMBL5658691

CS(=O)(=O)N1CCN(CC(=O)Nc2ccc(Oc3ccccc3)cc2)CC1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
GAA P10253 2/20 0.74
MAPT P10636 4/20 0.69
ALDH1A1 P00352 6/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
GLA P06280 1/20 0.68
HPGD P15428 3/20 0.67
RECQL P46063 1/20 0.63
LTA4H P09960 2/20 0.62
TSHR P16473 1/20 0.61
CHRNB2 P17787 2/20 0.59
CHRNB4 P30926 2/20 0.59
CHRNA3 P32297 2/20 0.59
CHRNA4 P43681 2/20 0.59
TDP1 Q9NUW8 1/20 0.58
ALOX15 P16050 1/20 0.58
KCNA5 P22460 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5661871 0.96 ALDH1A1 (0.69) LMNASMN1; SMN2GAAMAPTALDH1A1
SCHEMBL5663066 0.85 LMNA (1.00) LMNASMN1; SMN2GAAMAPTALDH1A1
SCHEMBL5658980 0.83 LMNA (0.77) LMNASMN1; SMN2GAAMAPTALDH1A1
SCHEMBL5312758 0.82 LTA4H (0.70) LMNASMN1; SMN2GAAMAPTALDH1A1
SCHEMBL5334244 0.82 ALDH1A1 (0.97) LMNASMN1; SMN2GAAMAPTALDH1A1
SCHEMBL5661923 0.81 LMNA (0.91) LMNASMN1; SMN2GAAMAPTALDH1A1
SCHEMBL5336327 0.80 ALDH1A1 (0.74) LMNASMN1; SMN2GAAMAPTALDH1A1
SCHEMBL5336810 0.80 ALDH1A1 (0.74) LMNASMN1; SMN2GAAMAPTALDH1A1
SCHEMBL5310083 0.80 ALDH1A1 (1.00) LMNASMN1; SMN2GAAMAPTALDH1A1
SCHEMBL5312332 0.80 CHRNB4 (0.64) LMNASMN1; SMN2GAAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase SCHERING AKTIENGESSELLSCHAFT (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S LMNA 1402/4885SMN1; SMN2 4751/4885GAA 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.